Neuroendocrine  ||| S:0 E:15 ||| NNP
and  ||| S:15 E:19 ||| CC
non-neuroendocrine  ||| S:19 E:38 ||| JJ
markers  ||| S:38 E:46 ||| NN
of  ||| S:46 E:49 ||| IN
inflammation  ||| S:49 E:62 ||| VBG
associated  ||| S:62 E:73 ||| VBN
with  ||| S:73 E:78 ||| IN
performance  ||| S:78 E:90 ||| NN
in  ||| S:90 E:93 ||| IN
endurance  ||| S:93 E:103 ||| JJ
horses  ||| S:103 E:110 ||| NNS
The  ||| S:110 E:114 ||| DT
inflammatory  ||| S:114 E:127 ||| JJ
and  ||| S:127 E:131 ||| CC
neuroendocrine  ||| S:131 E:146 ||| JJ
response  ||| S:146 E:155 ||| NN
to  ||| S:155 E:158 ||| TO
endurance  ||| S:158 E:168 ||| VB
exercise  ||| S:168 E:177 ||| NN
and  ||| S:177 E:181 ||| CC
relationship  ||| S:181 E:194 ||| NN
of  ||| S:194 E:197 ||| IN
these  ||| S:197 E:203 ||| DT
parameters  ||| S:203 E:214 ||| NN
to  ||| S:214 E:217 ||| TO
performance  ||| S:217 E:229 ||| NN
is  ||| S:229 E:232 ||| VBZ
not  ||| S:232 E:236 ||| RB
well  ||| S:236 E:241 ||| RB
documented  ||| S:241 E:252 ||| VBN
in  ||| S:252 E:255 ||| IN
horses ||| S:255 E:261 ||| NNS
.  ||| S:261 E:263 ||| .
HYPOTHESES  ||| S:263 E:274 ||| NNP
OR  ||| S:274 E:277 ||| NNP
OBJECTIVES ||| S:277 E:287 ||| NNP
:  ||| S:287 E:289 ||| :
Evidence  ||| S:289 E:298 ||| NN
of  ||| S:298 E:301 ||| IN
systemic  ||| S:301 E:310 ||| JJ
inflammation  ||| S:310 E:323 ||| NN
is  ||| S:323 E:326 ||| VBZ
associated  ||| S:326 E:337 ||| VBN
with  ||| S:337 E:342 ||| IN
poor  ||| S:342 E:347 ||| JJ
performance  ||| S:347 E:359 ||| NN
in  ||| S:359 E:362 ||| IN
horses  ||| S:362 E:369 ||| NNS
competing  ||| S:369 E:379 ||| VBG
in  ||| S:379 E:382 ||| IN
endurance  ||| S:382 E:392 ||| JJ
events ||| S:392 E:398 ||| NNS
.  ||| S:398 E:400 ||| .
Blood  ||| S:400 E:406 ||| NN
was  ||| S:406 E:410 ||| VBD
collected  ||| S:410 E:420 ||| VBN
prior  ||| S:420 E:426 ||| RB
to  ||| S:426 E:429 ||| TO
and  ||| S:429 E:433 ||| CC
at  ||| S:433 E:436 ||| IN
the  ||| S:436 E:440 ||| DT
finish  ||| S:440 E:447 ||| NN
or  ||| S:447 E:450 ||| CC
elimination  ||| S:450 E:462 ||| NN
point  ||| S:462 E:468 ||| NN
from  ||| S:468 E:473 ||| IN
horses  ||| S:473 E:480 ||| NNS
competing  ||| S:480 E:490 ||| VBG
in  ||| S:490 E:493 ||| IN
both  ||| S:493 E:498 ||| PDT
the  ||| S:498 E:502 ||| DT
80  ||| S:502 E:505 ||| CD
and  ||| S:505 E:509 ||| CC
160  ||| S:509 E:513 ||| CD
km  ||| S:513 E:516 ||| JJ
American  ||| S:516 E:525 ||| NNP
Endurance  ||| S:525 E:535 ||| NNP
Ride  ||| S:535 E:540 ||| NNP
National  ||| S:540 E:549 ||| NNP
Championship  ||| S:549 E:562 ||| NNP
competitions  ||| S:562 E:575 ||| NNS
in  ||| S:575 E:578 ||| IN
2006 ||| S:578 E:582 ||| CD
.  ||| S:582 E:584 ||| .
Immunoreactive  ||| S:584 E:599 ||| FW
alpha-melanocyte  ||| S:599 E:616 ||| FW
stimulating  ||| S:616 E:628 ||| FW
hormone  ||| S:628 E:636 ||| FW
( ||| S:636 E:637 ||| -LRB-
α-MSH ||| S:637 E:642 ||| NNP
)  ||| S:642 E:644 ||| -RRB-
and  ||| S:644 E:648 ||| CC
tumour  ||| S:648 E:655 ||| FW
necrosis  ||| S:655 E:664 ||| FW
factor-alpha  ||| S:664 E:677 ||| FW
( ||| S:677 E:678 ||| -LRB-
TNF-α ||| S:678 E:683 ||| NNP
)  ||| S:683 E:685 ||| -RRB-
were  ||| S:685 E:690 ||| VBD
quantified  ||| S:690 E:701 ||| VBN
utilising  ||| S:701 E:711 ||| JJ
radioimmunoassay  ||| S:711 E:728 ||| NNS
( ||| S:728 E:729 ||| -LRB-
RIA ||| S:729 E:732 ||| NNP
)  ||| S:732 E:734 ||| -RRB-
and  ||| S:734 E:738 ||| CC
enzyme-linked  ||| S:738 E:752 ||| JJ
immunosorbent  ||| S:752 E:766 ||| JJ
assay  ||| S:766 E:772 ||| NNS
( ||| S:772 E:773 ||| -LRB-
ELISA ||| S:773 E:778 ||| NNP
)  ||| S:778 E:780 ||| -RRB-
techniques ||| S:780 E:790 ||| NNS
,  ||| S:790 E:792 ||| ,
respectively ||| S:792 E:804 ||| RB
.  ||| S:804 E:806 ||| .
The  ||| S:806 E:810 ||| DT
concentration  ||| S:810 E:824 ||| NN
of  ||| S:824 E:827 ||| IN
total  ||| S:827 E:833 ||| JJ
thiobarbituric  ||| S:833 E:848 ||| FW
acid  ||| S:848 E:853 ||| FW
reactive  ||| S:853 E:862 ||| FW
substances  ||| S:862 E:873 ||| FW
( ||| S:873 E:874 ||| -LRB-
TBARS ||| S:874 E:879 ||| NNP
)  ||| S:879 E:881 ||| -RRB-
was  ||| S:881 E:885 ||| VBD
measured  ||| S:885 E:894 ||| VBN
fluorometrically ||| S:894 E:910 ||| NN
.  ||| S:910 E:912 ||| .
Thirty  ||| S:912 E:919 ||| JJ
horses  ||| S:919 E:926 ||| NNS
were  ||| S:926 E:931 ||| VBD
included  ||| S:931 E:940 ||| VBN
in  ||| S:940 E:943 ||| IN
the  ||| S:943 E:947 ||| DT
study ||| S:947 E:952 ||| NN
.  ||| S:952 E:954 ||| .
Endurance  ||| S:954 E:964 ||| JJ
exercise  ||| S:964 E:973 ||| NN
was  ||| S:973 E:977 ||| VBD
associated  ||| S:977 E:988 ||| VBN
with  ||| S:988 E:993 ||| IN
a  ||| S:993 E:995 ||| DT
significant  ||| S:995 E:1007 ||| JJ
increase  ||| S:1007 E:1016 ||| NN
in  ||| S:1016 E:1019 ||| IN
TBARS  ||| S:1019 E:1025 ||| NNP
in  ||| S:1025 E:1028 ||| IN
the  ||| S:1028 E:1032 ||| DT
80  ||| S:1032 E:1035 ||| CD
km  ||| S:1035 E:1038 ||| JJ
group  ||| S:1038 E:1044 ||| NN
but  ||| S:1044 E:1048 ||| CC
not  ||| S:1048 E:1052 ||| RB
the  ||| S:1052 E:1056 ||| DT
160  ||| S:1056 E:1060 ||| CD
km  ||| S:1060 E:1063 ||| JJ
group ||| S:1063 E:1068 ||| NN
.  ||| S:1068 E:1070 ||| .
TNF-α  ||| S:1070 E:1076 ||| NNP
and  ||| S:1076 E:1080 ||| CC
α-MSH  ||| S:1080 E:1086 ||| NNP
did  ||| S:1086 E:1090 ||| VBD
not  ||| S:1090 E:1094 ||| RB
significantly  ||| S:1094 E:1108 ||| RB
change  ||| S:1108 E:1115 ||| VB
as  ||| S:1115 E:1118 ||| IN
a  ||| S:1118 E:1120 ||| DT
result  ||| S:1120 E:1127 ||| NN
of  ||| S:1127 E:1130 ||| IN
exercise  ||| S:1130 E:1139 ||| NN
in  ||| S:1139 E:1142 ||| IN
either  ||| S:1142 E:1149 ||| DT
distance  ||| S:1149 E:1158 ||| NN
group ||| S:1158 E:1163 ||| NN
.  ||| S:1163 E:1165 ||| .
Precompetition  ||| S:1165 E:1180 ||| NNP
TBARS  ||| S:1180 E:1186 ||| NNP
was  ||| S:1186 E:1190 ||| VBD
significantly  ||| S:1190 E:1204 ||| RB
higher  ||| S:1204 E:1211 ||| JJR
in  ||| S:1211 E:1214 ||| IN
horses  ||| S:1214 E:1221 ||| NNS
that  ||| S:1221 E:1226 ||| WDT
failed  ||| S:1226 E:1233 ||| VBD
to  ||| S:1233 E:1236 ||| TO
finish  ||| S:1236 E:1243 ||| VB
the  ||| S:1243 E:1247 ||| DT
80  ||| S:1247 E:1250 ||| CD
km  ||| S:1250 E:1253 ||| JJ
race ||| S:1253 E:1257 ||| NN
,  ||| S:1257 E:1259 ||| ,
as  ||| S:1259 E:1262 ||| RB
well  ||| S:1262 E:1267 ||| RB
as  ||| S:1267 E:1270 ||| IN
when  ||| S:1270 E:1275 ||| WRB
distances  ||| S:1275 E:1285 ||| NNS
were  ||| S:1285 E:1290 ||| VBD
combined ||| S:1290 E:1298 ||| VBN
.  ||| S:1298 E:1300 ||| .
In  ||| S:1300 E:1303 ||| IN
addition ||| S:1303 E:1311 ||| NN
,  ||| S:1311 E:1313 ||| ,
precompetition  ||| S:1313 E:1328 ||| JJ
α-MSH  ||| S:1328 E:1334 ||| NN
was  ||| S:1334 E:1338 ||| VBD
significantly  ||| S:1338 E:1352 ||| RB
lower  ||| S:1352 E:1358 ||| JJR
in  ||| S:1358 E:1361 ||| IN
nonfinishers  ||| S:1361 E:1374 ||| NN
in  ||| S:1374 E:1377 ||| IN
the  ||| S:1377 E:1381 ||| DT
160  ||| S:1381 E:1385 ||| CD
km  ||| S:1385 E:1388 ||| JJ
group ||| S:1388 E:1393 ||| NN
.  ||| S:1393 E:1395 ||| .
Furthermore ||| S:1395 E:1406 ||| RB
,  ||| S:1406 E:1408 ||| ,
competition  ||| S:1408 E:1420 ||| NN
speed  ||| S:1420 E:1426 ||| NN
was  ||| S:1426 E:1430 ||| VBD
positively  ||| S:1430 E:1441 ||| RB
correlated  ||| S:1441 E:1452 ||| VBN
with  ||| S:1452 E:1457 ||| IN
precompetition  ||| S:1457 E:1472 ||| JJ
α-MSH  ||| S:1472 E:1478 ||| NN
in  ||| S:1478 E:1481 ||| IN
the  ||| S:1481 E:1485 ||| DT
80  ||| S:1485 E:1488 ||| CD
km  ||| S:1488 E:1491 ||| NNS
and  ||| S:1491 E:1495 ||| CC
negatively  ||| S:1495 E:1506 ||| RB
correlated  ||| S:1506 E:1517 ||| VBN
with  ||| S:1517 E:1522 ||| IN
precompetition  ||| S:1522 E:1537 ||| JJ
TNF-α  ||| S:1537 E:1543 ||| NN
when  ||| S:1543 E:1548 ||| WRB
distances  ||| S:1548 E:1558 ||| NNS
were  ||| S:1558 E:1563 ||| VBD
combined ||| S:1563 E:1571 ||| VBN
.  ||| S:1571 E:1573 ||| .
Our  ||| S:1573 E:1577 ||| PRP$
results  ||| S:1577 E:1585 ||| NNS
suggest  ||| S:1585 E:1593 ||| VBP
that  ||| S:1593 E:1598 ||| IN
basal  ||| S:1598 E:1604 ||| JJ
oxidative  ||| S:1604 E:1614 ||| JJ
stress  ||| S:1614 E:1621 ||| NN
markers ||| S:1621 E:1628 ||| NN
,  ||| S:1628 E:1630 ||| ,
circulating  ||| S:1630 E:1642 ||| VBG
cytokines  ||| S:1642 E:1652 ||| NNS
and  ||| S:1652 E:1656 ||| CC
anti-inflammatory  ||| S:1656 E:1674 ||| JJ
neuroendocrine  ||| S:1674 E:1689 ||| JJ
hormones  ||| S:1689 E:1698 ||| NNS
appear  ||| S:1698 E:1705 ||| VBP
to  ||| S:1705 E:1708 ||| TO
correlate  ||| S:1708 E:1718 ||| VB
with  ||| S:1718 E:1723 ||| IN
endurance  ||| S:1723 E:1733 ||| JJ
performance  ||| S:1733 E:1745 ||| NN
in  ||| S:1745 E:1748 ||| IN
horses ||| S:1748 E:1754 ||| NNS
.  ||| S:1754 E:1756 ||| .
Basal  ||| S:1756 E:1762 ||| JJ
oxidative  ||| S:1762 E:1772 ||| JJ
stress  ||| S:1772 E:1779 ||| NN
markers ||| S:1779 E:1786 ||| NN
,  ||| S:1786 E:1788 ||| ,
circulating  ||| S:1788 E:1800 ||| VBG
cytokines  ||| S:1800 E:1810 ||| NNS
and  ||| S:1810 E:1814 ||| CC
anti-inflammatory  ||| S:1814 E:1832 ||| JJ
neuroendocrine  ||| S:1832 E:1847 ||| JJ
hormones  ||| S:1847 E:1856 ||| NNS
may  ||| S:1856 E:1860 ||| MD
be  ||| S:1860 E:1863 ||| VB
predictive  ||| S:1863 E:1874 ||| VBN
of  ||| S:1874 E:1877 ||| IN
athletic  ||| S:1877 E:1886 ||| JJ
performance  ||| S:1886 E:1898 ||| NN
in  ||| S:1898 E:1901 ||| IN
endurance  ||| S:1901 E:1911 ||| JJ
horses ||| S:1911 E:1917 ||| NNS
.  ||| S:1917 E:1919 ||| .
Future  ||| S:1919 E:1926 ||| JJ
studies  ||| S:1926 E:1934 ||| NNS
evaluating  ||| S:1934 E:1945 ||| VBG
the  ||| S:1945 E:1949 ||| DT
effect  ||| S:1949 E:1956 ||| NN
of  ||| S:1956 E:1959 ||| IN
training  ||| S:1959 E:1968 ||| NN
on  ||| S:1968 E:1971 ||| IN
these  ||| S:1971 E:1977 ||| DT
markers  ||| S:1977 E:1985 ||| NN
in  ||| S:1985 E:1988 ||| IN
endurance  ||| S:1988 E:1998 ||| JJ
horses  ||| S:1998 E:2005 ||| NNS
are  ||| S:2005 E:2009 ||| VBP
warranted ||| S:2009 E:2018 ||| VBN
.  ||| S:2018 E:2020 ||| .
